Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for retinal diseases, has appointed Aaron Osborne, MBBS, as Chief Medical Officer and Chief Development Officer. He is joined by recent hires Anil Lalwani, MS, MBA, Vice President of CMC and Quality, and Jared Stephens, PhD, Vice President of Strategy and BD.   “We are excited to welcome these experienced biopharmaceutical executives,” said Sulagna Bhattacharya, Nanoscope CEO. “They ...